Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

Invited presentations and discussions may: Review the current state of knowledge regarding the mechanisms of action of GLP-1R agonists and their therapeutic applications across different disease areas ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Liraglutide was shown to rapidly improve insulin sensitivity as well as decrease blood glucose within two weeks of beginning treatment and before any weight loss. "GLP-1R agonists are an exciting ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist ... and on par with antibody conjugated NuSH analogs.” As for safety, gastrointestinal adverse events ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns ...

Skye said that no neuropsychiatric adverse events were observed in Phase 1 data for its monoclonal antibody nimacimab ... with topline data in Q4 2025. The GLP-1R agonist drug being assessed ...